Monte Rosa Therapeutics, Inc.

NASDAQ:GLUE

Biotechnology

Healthcare
$8.91 -1.39%

-$0.26 today

Market cap
$761.36M
Beta
1.60
P/E (TTM)
-9.1
EPS (TTM)
-$1.98
52W Low $4.12High $25.77

Volume 1.11M

Average 1.02M

Income Statement

Follow revenue through to earnings.

Revenue

$123.67M

FY 2025 · Annual

+63.5% YoY

Operating Income

-$54.21M

FY 2025 · Annual

Net Income

-$38.63M

FY 2025 · Annual

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00075.62M123.67M
Cost of Revenue006.22M8.12M8.36M
Gross Profit00(6.22M)67.5M115.32M
Gross Margin———89.3%93.2%
Research & Development57.16M85.06M105.05M121.56M141.5M
Selling, General & Admin15.73M27.32M32.04M35.17M36.38M
Operating Expenses72.88M112.38M137.09M148.61M169.52M
Depreciation & Amortization2.13M3.75M6.22M8.12M8.36M
EBITDA(71.83M)(100.99M)(128.79M)(62.01M)(31.37M)
EBITDA Margin———-82.0%-25.4%
Operating Income(72.88M)(112.38M)(143.31M)(81.11M)(54.21M)
Operating Margin———-107.3%-43.8%
Interest Income46K3.76M9.33M10.57M12.94M
Interest Expense03.76M000
Other Income / Expenses(1.08M)3.88M8.3M10.98M14.49M
Income Before Tax(73.96M)(108.5M)(135.01M)(70.13M)(39.72M)
Pre-Tax Margin———-92.7%-32.1%
Income Tax Expense00338K2.57M(1.1M)
Net Income(73.96M)(108.5M)(135.35M)(72.7M)(38.63M)
Net Margin———-96.1%-31.2%
EPS (Basic)(1.59)(2.30)(2.63)(0.98)(0.46)
EPS (Diluted)(1.59)(2.30)(2.63)(0.98)(0.46)
Weighted Avg Shares46.54M47.23M51.4M73.91M83.07M
Weighted Avg Shares (Diluted)46.54M47.23M51.4M73.91M83.07M

GLUE Earnings Waterfall · TTM

NASDAQ:GLUE · Revenue to Net Income

Key Ratios

EPS$-1.86
Gross Margin88.0%
Net Margin-745.3%
P/E Ratio-6.2
P/S Ratio172.4

Analysis

$43.0M of revenue converted into -$130.0M of net income for the selected period. Gross margin is 88.0% and net margin is -745.3%, showing how much revenue survives after costs and taxes. EPS is $-1.86, tying the income statement back to per-share earnings.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
8-KCurrent reportNov 5, 2026
10-QQuarterly reportNov 5, 2026
4Statement of changes in beneficial ownershipOct 6, 2026
8-KCurrent reportOct 1, 2026
8-KCurrent reportSep 8, 2026

How much revenue does GLUE generate?

Monte Rosa Therapeutics, Inc. (GLUE) reported $123.67M of revenue in fiscal 2025.

Is GLUE profitable?

Monte Rosa Therapeutics, Inc. (GLUE) reported -$38.63M of net income, with a net margin of -31.2%.